Date:2021.12.13
Your Name: Zizheng Song
Manuscript Title: Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V
mutation-mediated resistance towards osimertinib: a case report and literature review
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_*_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	×_ None	
3	Royalties or licenses	*_None	
4	Consulting fees	_ * _None	

5	Payment or honoraria for	_ x _None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_ x _None	
	testimony		
7	Support for attending meetings and/or travel	_ × _None	
	meetings and, or traver		
8	Patents planned, issued or	_ x _None	
	pending		
9	Participation on a Data	_ x _None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ x _None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_ x_ None	
12	Receipt of equipment,	_ ×_ None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	× None	
	financial interests		

The author has no conflicts of interest to declare.		

Please place an "X" next to the following statement to indicate your agreement:

Date:2021.12.13
Your Name: Guanying Ren
Manuscript Title: Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718'
mutation-mediated resistance towards osimertinib: a case report and literature review
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_*_None	
2	Grants or contracts from any entity (if not indicated	Time frame: past*_ None	36 months
	in item #1 above).		
3	Royalties or licenses	× _None	
4	Consulting fees	×_ None	

5	Payment or honoraria for	_ x _None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_ x _None	
	testimony		
7	Support for attending meetings and/or travel	_ × _None	
	meetings and, or traver		
8	Patents planned, issued or	_ x _None	
	pending		
9	Participation on a Data	_ x _None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ x _None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_ x_ None	
12	Receipt of equipment,	_ ×_ None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	× None	
	financial interests		

The author has no conflicts of interest to declare.		

Please place an "X" next to the following statement to indicate your agreement:

Date:2021.12.13
Your Name: Xiaolei Wang
Manuscript Title: Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718V
mutation-mediated resistance towards osimertinib: a case report and literature review
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_*_None	
2	Grants or contracts from any entity (if not indicated	Time frame: past*_ None	36 months
	in item #1 above).		
3	Royalties or licenses	× _None	
4	Consulting fees	×_ None	

5	Payment or honoraria for	_ x _None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_ x _None	
	testimony		
7	Support for attending meetings and/or travel	_ × _None	
	meetings and, or traver		
8	Patents planned, issued or	_ x _None	
	pending		
9	Participation on a Data	_ x _None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ x _None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_ x_ None	
12	Receipt of equipment,	_ ×_ None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	× None	
	financial interests		

The author has no conflicts of interest to declare.		

Please place an "X" next to the following statement to indicate your agreement:

Date:2021.12.13
Your Name: Haiwei Du
Manuscript Title: Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGFR L718
mutation-mediated resistance towards osimertinib: a case report and literature review
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_*_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	×_ None	
3	Royalties or licenses	*_None	
4	Consulting fees	_ * _None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	_ × _None	
	manuscript writing or educational events		
6	Payment for expert testimony	×_ None	
7	Support for attending meetings and/or travel	_*_None	
8	Patents planned, issued or pending	_×_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ x _None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	*_None	
11	Stock or stock options	×_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_*_None	
13	Other financial or non- financial interests	None	Burning Rock Biotech, Guangzhou, China

This author is from Burning Rock Biotech, Guangzhou, China.		

Please place an "X" next to the following statement to indicate your agreement:

Date:2021.12.13	_
Your Name: Ying Sun	
Manuscript Title: Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired EGF	R L718\
mutation-mediated resistance towards osimertinib: a case report and literature review	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_*_None	
2	Grants or contracts from any entity (if not indicated	Time frame: past*_ None	36 months
	in item #1 above).		
3	Royalties or licenses	× _None	
4	Consulting fees	×_ None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	_ × _None	
	manuscript writing or educational events		
6	Payment for expert testimony	×_ None	
7	Support for attending meetings and/or travel	_*_None	
8	Patents planned, issued or pending	_×_None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_ x _None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	*_None	
11	Stock or stock options	×_None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	_*_None	
13	Other financial or non- financial interests	None	Burning Rock Biotech, Guangzhou, China

This author is from Burning Rock Biotech, Guangzhou, China.		

Please place an "X" next to the following statement to indicate your agreement:

Date:2021.12.13	
Your Name: Ling Hu	
Manuscript Title: Durable clinical benefit from afatinib in a lung adenocarcinoma patient with acquired E	GFR L718V
mutation-mediated resistance towards osimertinib: a case report and literature review	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_*_None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	_×_ None	
3	Royalties or licenses	*_None	
4	Consulting fees	× _None	

5	Payment or honoraria for	_ x _None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_ x _None	
	testimony		
7	Support for attending meetings and/or travel	_ × _None	
	meetings and, or traver		
8	Patents planned, issued or	_ x _None	
	pending		
9	Participation on a Data	_ x _None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ x _None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	_ x_ None	
12	Receipt of equipment,	_ ×_ None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	× None	
	financial interests		

The author has no conflicts of interest to declare.		

Please place an "X" next to the following statement to indicate your agreement: